Although SGLT2 inhibitors are not approved for the treatment of obesity, they can be used to treat important obesity complications specifically in patients with type 2 diabetes, HFpEF or HFrEF and chronic kidney disease. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.